GlassScriptPhysician profile
Matthew Lindquist
NPI 1710969159
$42,243.53
in general payments reported to CMS, 2019-2025
27 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,672 · 2022: $12K · 2023: $9,427 · 2024: $11K · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $5,554 · Travel and Lodging: $3,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,731.59 |
| Food and Beverage | $5,554.28 |
| Travel and Lodging | $3,851.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $26,733.14 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $3,883.67 | 2021-2024 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,536.86 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,613.59 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Neurocrine Biosciences, INC. | $1,208.77 | 2021-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $920.41 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $772.01 | 2021-2023 | Invega Sustenna |
| Validus Pharmaceuticals LLC | $737.04 | 2021-2024 | Equetro |
| Abbvie INC. | $638.73 | 2021-2023 | |
| Vanda Pharmaceuticals INC. | $601.30 | 2021-2024 | Fanapt |
| Axsome Therapeutics, INC. | $583.99 | 2023-2024 | Auvelity, Sunosi |
| Lundbeck LLC | $372.11 | 2021-2023 | Rexulti |
| Noven Therapeutics, LLC | $324.02 | 2021-2023 | Secuado |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $191.17 | 2021-2024 | Abilify Asimtufii |
| Livanova USA, INC. | $170.44 | 2022-2023 | Vns Therapy Symmetry Model 8103 Generator |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $164.85 | 2024-2025 | Fasenra |
| Indivior INC. | $161.31 | 2021-2023 | Perseris |
| Acadia Pharmaceuticals INC | $125.00 | 2021 | |
| Neurelis, INC. | $122.11 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $121.17 | 2025 | Cobenfy |
| Orexo US, INC. | $50.02 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.90 | 2021 | |
| Noven Pharmaceuticals, INC. | $45.49 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.25 | 2022 | |
| Almatica Pharma LLC | $40.57 | 2021-2023 | Loreev Xr |
| Bioxcel Therapeutics, INC. | $21.15 | 2023 | Igalmi |
| Janssen Biotech, INC. | $14.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lindquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.